A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity
Open Access
- 16 May 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5), e36833
- https://doi.org/10.1371/journal.pone.0036833
Abstract
Fusion between the viral and target cell membranes is an obligatory step for the infectivity of all enveloped virus, and blocking this process is a clinically validated therapeutic strategy. Viral fusion is driven by specialized proteins which, although specific to each virus, act through a common mechanism, the formation of a complex between two heptad repeat (HR) regions. The HR regions are initially separated in an intermediate termed “prehairpin”, which bridges the viral and cell membranes, and then fold onto each other to form a 6-helical bundle (6HB), driving the two membranes to fuse. HR-derived peptides can inhibit viral infectivity by binding to the prehairpin intermediate and preventing its transition to the 6HB. The antiviral activity of HR-derived peptides differs considerably among enveloped viruses. For weak inhibitors, potency can be increased by peptide engineering strategies, but sequence-specific optimization is time-consuming. In seeking ways to increase potency without changing the native sequence, we previously reported that attachment to the HR peptide of a cholesterol group (”cholesterol-tagging”) dramatically increases its antiviral potency, and simultaneously increases its half-life in vivo. We show here that antiviral potency may be increased by combining cholesterol-tagging with dimerization of the HR-derived sequence, using as examples human parainfluenza virus, Nipah virus, and HIV-1. Together, cholesterol-tagging and dimerization may represent strategies to boost HR peptide potency to levels that in some cases may be compatible with in vivo use, possibly contributing to emergency responses to outbreaks of existing or novel viruses.This publication has 64 references indexed in Scilit:
- Dependence of Avidity on Linker Length for a Bivalent Ligand–Bivalent Receptor Model SystemJournal of the American Chemical Society, 2011
- Designed oligomers of cyanovirin-N show enhanced HIV neutralizationProceedings of the National Academy of Sciences of the United States of America, 2011
- Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeuticProceedings of the National Academy of Sciences of the United States of America, 2010
- Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potencyProceedings of the National Academy of Sciences of the United States of America, 2010
- Lipids and membrane microdomains in HIV-1 replicationVirus Research, 2009
- Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potencyProceedings of the National Academy of Sciences of the United States of America, 2009
- Potent D-peptide inhibitors of HIV-1 entryProceedings of the National Academy of Sciences of the United States of America, 2007
- Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virusProceedings of the National Academy of Sciences of the United States of America, 2007
- MultiCoil: A program for predicting two‐and three‐stranded coiled coilsProtein Science, 1997
- Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.Proceedings of the National Academy of Sciences of the United States of America, 1996